Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMP1 | P13497 | 2/20 | 0.46 |
| ▸ | CCR6 | P51684 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 5/20 | 0.43 |
| ▸ | MMP9 | P14780 | 5/20 | 0.43 |
| ▸ | MMP13 | P45452 | 5/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22718248 | 0.92 | PTGER2 (0.41) | BMP1MMP1MMP9MMP13MAPT | |
| SCHEMBL22718006 | 0.91 | BMP1 (0.50) | BMP1CCR6MMP1MMP9MMP13 | |
| SCHEMBL22718278 | 0.89 | CA12 (0.40) | BMP1MMP1MMP9MMP13KDM4E | |
| SCHEMBL22718201 | 0.89 | BMP1 (0.45) | BMP1MMP1MMP9MMP13MDM2 | |
| SCHEMBL24497371 | 0.88 | BMP1 (0.44) | BMP1CCR6MMP1MMP9MMP13 | |
| SCHEMBL29648392 | 0.88 | BMP1 (0.44) | BMP1CCR6MMP1MMP9MMP13 | |
| SCHEMBL24497405 | 0.87 | MAPT (0.44) | BMP1CCR6MMP1MMP9MMP13 | |
| SCHEMBL29648375 | 0.87 | MAPT (0.44) | BMP1CCR6MMP1MMP9MMP13 | |
| SCHEMBL24496385 | 0.87 | BMP1 (0.43) | BMP1MMP1MMP9MMP13MDM2 | |
| SCHEMBL22718297 | 0.86 | CA12 (0.42) | BMP1MMP1MMP9MMP13KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577208-B2 | TEAD inhibitors and uses thereof | EHE Foundation (US) | 2026-03-17 | — | — | US | disclosed |
| CN-119954725-A | TEAD inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-114466839-B | TEAD inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2025-01-07 | — | — | CN | disclosed |
| US-20240261288-A1 | COMBINATION OF A 3-(IMIDAZOL-4-YL)-4-(AMINO)-BENZENESULFONAMIDE TEAD INHIBITOR WITH AN EGFR INHIBITOR AND/OR MEK INHIBITOR FOR USE IN THE TREATMENT OF LUNG CANCER | THE EHE FOUNDATION | 2024-08-08 | — | — | US | disclosed |
| US-20240083854-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2024-03-14 | — | — | US | disclosed |
| EP-4255895-A1 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2023-10-11 | — | — | EP | disclosed |
| US-11760728-B2 | Tead inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760728-B2 | Tead inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760728-B2 | Tead inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2023-09-19 | — | — | US | disclosed |
| CN-115594680-A | TEAD inhibitor | 武汉人福创新药物研发中心有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| WO-2022120354-A1 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2022-06-09 | — | — | WO | disclosed |
| WO-2022120353-A1 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2022-06-09 | — | — | WO | disclosed |
| WO-2022120353-A1 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2022-06-09 | — | — | WO | disclosed |
| WO-2022120355-A1 | TEAD DEGRADERS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2022-06-09 | — | — | WO | disclosed |
| WO-2022120355-A1 | TEAD DEGRADERS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2022-06-09 | — | — | WO | disclosed |
| EP-3976194-A2 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| US-11274082-B2 | Tead inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20200407327-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2020-12-31 | — | — | US | disclosed |
| WO-2020243415-A2 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2020-12-03 | — | — | WO | disclosed |
| WO-2020243415-A2 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2020-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240261288-A1 | COMBINATION OF A 3-(IMIDAZOL-4-YL)-4-(AMINO)-BENZENESULFONAMIDE TEAD INHIBITOR WITH AN EGFR INHIBITOR AND/OR MEK INHIBITOR FOR USE IN THE TREATMENT OF LUNG CANCER | EGFR, ERBB2, ERBB4 | BMP1 3770/4885CCR6 3501/4885MMP1 3034/4885 |
| US-11274082-B2 | Tead inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | BMP1 4218/4885CCR6 4335/4885MMP1 872/4885 |
| US-20240083854-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | BMP1 4218/4885CCR6 4335/4885MMP1 872/4885 |
| US-11760728-B2 | Tead inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | BMP1 4218/4885CCR6 4335/4885MMP1 872/4885 |
| US-12577208-B2 | TEAD inhibitors and uses thereof | BRCA1, BRAF, MEN1 | BMP1 797/4885CCR6 2313/4885MMP1 2180/4885 |
| US-20200407327-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | BMP1 4218/4885CCR6 4335/4885MMP1 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.